Combination immunohistochemistry for CK5/6, p63, GATA6, and HNF4a predicts clinical outcome in treatment-naïve pancreatic ductal adenocarcinoma. This evidence concerns the gene GATA6 and pancreatic ductal adenocarcinoma.